International Journal of Ophthalmic PathologyISSN: 2324-8599

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Clinical Image, Int J Ophthalmic Pathol Vol: 4 Issue: 4

Stop Medication to Avoid Oculoplastic Surgery: Prostaglandin-Associated Periorbitopathy

Maya Kalev-Landoy1,2* and Asaf Achiron1,2
1Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel
2Sackler School of Medicine, Tel Aviv University, Israel
Corresponding author : Maya Kalev-Landoy
Department of Ophthalmology, Edith Wolfson Medical Center, 62 Halochamim St Holon, Israel 58100
Tel: +972-3-5028706
E-mail: [email protected]
Received: October 19, 2015 Accepted: November 04, 2015 Published: November 06, 2015
Citation: Landoy and Achiron (2015) Stop Medication to Avoid Oculoplastic Surgery: Prostaglandin–Associated Periorbitopathy. Int J Ophthalmic Pathol 4:4 doi:10.4172/2324-8599.1000171

Abstract

A 65 year old patient was diagnosed with ocular hypertension his right eye (RE) and pseudoexfoliative glaucoma in his left eye (LE). He was treated bilaterally for several years with Lumigan (Bimatoprost 0.03%). However, in 2010 his LE intraocular pressure (IOP) was no longer medically controlled and he underwent a trabeculectomy surgery. LE IOP was subsequently controlled, without any medications. The patient continued to take the Lumigan to control IOP in his RE. On April 2014 the patient requested a referral for oculoplastic surgery (LE blepharoplasty), to treat a disturbing asymmetry in his eyes appearance. On examination we observed blepharochalasis in the LE which was prominent due to severe prostaglandin-associated periorbitopathy (PAP) in the RE, (Figure 1). RE Lumigan was stopped and we started him on Betoptic-S (Betaxolol HCl 0.25%). 5 months later we observed a symmetric blepharochalasis bilaterally and disappearance of the LE PAP, (Figure 2). The Patient was content and was not interested in further intervention.

The mechanism behind PAP include activation of prostaglandin F receptors, which are highly concentrated the in the eyelid tissue, cause an inhibition of preadipocyte differentiation. Orbital fat atrophy, due to lipolysis of adipocytes, leads to the loss preaponeurotic fat and upper eyelid fullness [3]. PAP is often reversible and discontinuation of PGAs is recommended when symptoms of patients overcome the need to reduce the IOP

Keywords: Periorbitopathy; Oculoplastic Surgery

Track Your Manuscript

Share This Page